David is a co-founder and the Chief Scientific Advisor at Medicxi. He is currently the Chairman/CEO of several Medicxi portfolio companies (including Morphogen-IX, Rebalance, Divide & Conquer, Methuselah Health and Z-Factor) and Co-Founder of The Foundation Institute for 21st Century Medicine. David also led Medicxi's investment in Padlock Therapeutics (acquired by Bristol-Myers Squibb) and co-founded XO1 (acquired by Janssen Pharmaceuticals). Prior to Medicxi, David was a venture partner with Index Ventures for four years, having joined the life sciences team in 2012.
Before joining Index, David founded Funxional Therapeutics and the out-sourced drug developers Total Scientific and RxCelerate. In addition, he led an internationally-recognised research group in Cambridge University's Department of Medicine, where he published more than 80 first author papers in leading journals including Nature, Science and Nature Medicine. David is the Chair of the Translation Awards Committee of the British Heart Foundation. He ran a widely-read blog on life sciences-related topics, DrugBaron, before moving his writings to Forbes.com, where he is a Contributor.
David has over 150 patents and patent applications in his name, and holds MA and PhD degrees in Natural Sciences from the University of Cambridge.